Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

Journal of Hospital Infection

Volumn 101, Issue 1, 2019, Pages 42-46

  Park, S Y ^a   Lee, J S ^a   Son, J S ^b   Ko, J H ^c   Peck, K R ^c   Jung, Y ^d   Woo, H J ^e   Joo, Y S ^d   Eom, J S ^a   Shi, H ^a  

^a Hallym University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Hallym University Sacred Heart Hospital   (South Korea)

^e Hallym University School of Medicine   (South Korea)

Author keywords

Healthcare worker; High risk exposure; Middle East respiratory syndrome coronavirus; Outbreak; Post exposure prophylaxis; Pre isolation pneumonia

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RIBAVIRIN; ANTIVIRUS AGENT; LOPINAVIR; RITONAVIR;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BACKACHE; CASE REPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ENDOTRACHEAL INTUBATION; FEMALE; FEVER; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERBILIRUBINEMIA; INFECTION RISK; INTENSIVE CARE UNIT; LEUKOPENIA; MALE; MIDDLE EAST RESPIRATORY SYNDROME; NAUSEA; PATIENT ISOLATION; PNEUMONIA; POST EXPOSURE PROPHYLAXIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMATITIS; ADVERSE DRUG REACTION; CORONAVIRUS INFECTION; INCIDENCE; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH PERSONNEL; HUMANS; INCIDENCE; LOPINAVIR; MALE; POST-EXPOSURE PROPHYLAXIS; RETROSPECTIVE STUDIES; RIBAVIRIN; RITONAVIR; YOUNG ADULT;

EID: 85056156511     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2018.09.005     Document Type: Article

References (10)

1. Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al Rabeeah, A.A., Cummings, D.A., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369 (2013), 407–416.
2. Kim, S.G., Healthcare workers infected with Middle East respiratory syndrome coronavirus and infection control. J Korean Med Assoc 58 (2015), 647–654.
3. World Health Organization, Laboratory testing for Middle East respiratory syndrome coronavirus – interim recommendations (revised). September 2014 Available at: http://www.who.int/csr/disease/coronavirus infections/en/ [last accessed October 2016].
4. Muller, M.A., Meyer, B., Corman, V.M., Al-Masri, M., Turkestani, A., Ritz, D., et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis, 15, 2015, 629.
5. Centers for Disease Control and Prevention, Interim infection prevention and control recommendations for hospitalized patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV). 2015 Available at: http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html [last accessed October 2016].
6. Hunter, J.C., Nguyen, D., Aden, B., Al Bandar, Z., Al Dhaheri, W., Abu Elkheir, K., et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis 22 (2016), 647–656.
7. Chan, J.F., Chan, K.H., Kao, R.Y., To, K.K., Zheng, B.J., Li, C.P., et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67 (2013), 606–616.
8. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58 (2014), 4875–4884.
9. Spanakis, N., Tsiodras, S., Haagmans, B.L., Raj, V.S., Pontikis, K., Koutsoukou, A., et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 44 (2014), 528–532.
10. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14 (2014), 1090–1095.